A review of the alterations in DNA methylation in esophageal squamous cell carcinoma

Surgery Today

Volumn 43, Issue 12, 2013, Pages 1355-1364

  Baba, Yoshifumi ^a   Watanabe, Masayuki ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Epigenetics; Esophageal cancer; LINE 1; Methylation

Indexed keywords

MICRORNA;

CPG ISLAND; DNA METHYLATION; DNA REPAIR; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; MISMATCH REPAIR; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DNA METHYLATION; DNA MISMATCH REPAIR; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MICRORNAS; MOLECULAR TARGETED THERAPY; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84877876074     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-012-0451-y     Document Type: Review

References (117)

1. Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin. 2010;60(6):376-92.
2. Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer. 2011;117(4):677-87.
3. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28(10):1057-68.
4. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17(3):330-9.
5. Cordaux R, Batzer MA. The impact of retrotransposons on human genome evolution. Nat Rev Genet. 2009;10(10): 691-703.
6. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241-52.
7. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3(4):253-66.
8. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1(2):239-59.
9. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300(5618):455.
10. Cheng X, Blumenthal RM. Mammalian DNA methyltransferases: a structural perspective. Structure. 2008;16(3):341-50.
11. Shen JC, Rideout WM 3rd, Jones PA. High frequency mutagenesis by a DNA methyltransferase. Cell. 1992;71(7):1073-80.
12. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001;20(24):3139-55.
13. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21(2):163-7.
14. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301(5895):89-92.
15. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300(5618):489-92.
16. Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K, Ida S, et al. Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19(8):2726-32.
17. Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, et al. LINE-1 Hypomethylation is Associated with a Poor Prognosis Among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma. Ann Surg. 2012;PMID: 23023202.
18. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1(1):55-67.
19. Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Ishida K, Saito K, et al. Aberrations of tumor-suppressor genes (p53, apc, mcc and Rb) in esophageal squamous-cell carcinoma. Int J Cancer. 1994;57(1):21-5.
20. Boynton RF, Blount PL, Yin J, Brown VL, Huang Y, Tong Y, et al. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA. 1992;89(8):3385-8.
21. Powell SM, Papadopoulos N, Kinzler KW, Smolinski KN, Meltzer SJ. APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology. 1994;107(6): 1759-63.
22. Zare M, Jazii FR, Alivand MR, Nasseri NK, Malekzadeh R, Yazdanbod M. Qualitative analysis of adenomatous polyposis coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer. 2009;9:24.
23. Kim YT, Park JY, Jeon YK, Park SJ, Song JY, Kang CH, et al. Aberrant promoter CpG island hypermethylation of the adenomatosis polyposis coli gene can serve as a good prognostic factor by affecting lymph node metastasis in squamous cell carcinoma of the esophagus. Dis Esophagus. 2009;22(2): 143-50.
24. Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, Kambara T, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut. 2007;56(1):13-9.
25. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4(2): 118-32.
26. Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer. 1999;80(9): 1366-72.
27. Guo M, Ren J, House MG, Qi Y, Brock MV, Herman JG. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2006;12(15):4515-22.
28. Lee EJ, Lee BB, Han J, Cho EY, Shim YM, Park J, et al. CpG island hypermethylation of E-cadherin (CDH1) and integrin alpha4 is associated with recurrence of early stage esophageal squamous cell carcinoma. Int J Cancer. 2008;123(9):2073-9.
29. Fukuoka T, Hibi K, Nakao A. Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma. Anticancer Res. 2006;26(5A):3333-5.
30. Takeno S, Noguchi T, Fumoto S, Kimura Y, Shibata T, Kawahara K. E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, Snail overexpression, and clinicopathologic implications. Am J Clin Pathol. 2004;122(1):78-84.
31. Si HX, Tsao SW, Lam KY, Srivastava G, Liu Y, Wong YC, et al. E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett. 2001;173(1):71-8.
32. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001;2(10):731-7.
33. Esteve A, Martel-Planche G, Sylla BS, Hollstein M, Hainaut P, Montesano R. Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int J Cancer. 1996;66(3):301-4.
34. Tarmin L, Yin J, Zhou X, Suzuki H, Jiang HY, Rhyu MG, et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res. 1994;54(23):6094-6.
35. Tokugawa T, Sugihara H, Tani T, Hattori T. Modes of silencing of p16 in development of esophageal squamous cell carcinoma. Cancer Res. 2002;62(17):4938-44.
36. Xing EP, Nie Y, Wang LD, Yang GY, Yang CS. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis. 1999;20(1):77-84.
37. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD, et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 1999;5(10):2704-13.
38. Wang J, Sasco AJ, Fu C, Xue H, Guo G, Hua Z, et al. Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17(1):118-25.
39. Ling Y, Huang G, Fan L, Wei L, Zhu J, Liu Y, et al. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma. J Clin Pathol. 2011;64(3):246-51.
40. Li B, Wang B, Niu LJ, Jiang L, Qiu CC. Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics. 2011;6(3):307-16.
41. Mohammad Ganji S, Miotto E, Callegari E, Sayehmiri K, Fereidooni F, Yazdanbod M, et al. Associations of risk factors obesity and occupational airborne exposures with CDKN2A/p16 aberrant DNA methylation in esophageal cancer patients. Dis Esophagus. 2010 Sep;23(7):597-602.
42. Taghavi N, Biramijamal F, Sotoudeh M, Khademi H, Malekzadeh R, Moaven O, et al. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. BMC Cancer. 2010;10:138.
43. Salam I, Hussain S, Mir MM, Dar NA, Abdullah S, Siddiqi MA, et al. Aberrant promoter methylation and reduced expression of p16 gene in esophageal squamous cell carcinoma from Kashmir valley: a high-risk area. Mol Cell Biochem. 2009;332(1-2): 51-8.
44. Maesawa C, Tamura G, Nishizuka S, Ogasawara S, Ishida K, Terashima M, et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res. 1996;56(17):3875-8.
45. Nie Y, Liao J, Zhao X, Song Y, Yang GY, Wang LD, et al. Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis. 2002;23(10):1713-20.
46. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M, et al. Methylation of the 50 CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res. 1998; 58(15):3429-34.
47. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res. 2003;63(13):3724-8.
48. Lee EJ, Lee BB, Kim JW, Shim YM, Hoseok I, Han J, et al. Aberrant methylation of fragile histidine triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. Eur J Cancer. 2006;42(7):972-80.
49. Tzao C, Sun GH, Tung HJ, Hsu HS, Hsu WH, Wang YC, et al. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma. Ann Thorac Surg. 2006;82(2):396-401 (discussion).
50. Guo XQ, Wang SJ, Zhang LW, Wang XL, Zhang JH, Guo W. DNA methylation and loss of protein expression in esophageal squamous cell carcinogenesis of high-risk area. J Exp Clin Cancer Res. 2007;26(4):587-94.
51. Soma T, Kaganoi J, Kawabe A, Kondo K, Imamura M, Shimada Y. Nicotine induces the fragile histidine triad methylation in human esophageal squamous epithelial cells. Int J Cancer. 2006;119(5):1023-7.
52. Liu ZM, Ding F, Guo MZ, Zhang LY, Wu M, Liu ZH. Downregulation of retinoic acid receptor-beta(2) expression is linked to aberrant methylation in esophageal squamous cell carcinoma cell lines. World J Gastroenterol. 2004;10(6):771-5.
53. Wang Y, Fang MZ, Liao J, Yang GY, Nie Y, Song Y, et al. Hypermethylation-associated inactivation of retinoic acid receptor beta in human esophageal squamous cell carcinoma. Clin Cancer Res. 2003;9(14):5257-63.
54. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, et al. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res. 2003;9(4):1441-5.
55. Wong ML, Tao Q, Fu L, Wong KY, Qiu GH, Law FB, et al. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma. Int J Oncol. 2006;28(3):767-73.
56. Yamaguchi S, Kato H, Miyazaki T, Sohda M, Kimura H, Ide M, et al. RASSF1A gene promoter methylation in esophageal cancer specimens. Dis Esophagus. 2005;18(4):253-6.
57. Mao WM, Li P, Zheng QQ, Wang CC, Ge MH, Hu FJ, et al. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer. Arch Med Res. 2011;42(3):182-8.
58. Vasavi M, Kiran V, Ravishankar B, Prabhakar B, Ahuja YR, Hasan Q. Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers. Cancer Biomark. 2010;7(1):1-10.
59. Matsumoto Y, Nagasaka T, Kambara T, Hoshizima N, Murakami J, Sasamoto H, et al. Microsatellite instability and clinicopathological features in esophageal squamous cell cancer. Oncol Rep. 2007;18(5):1123-7.
60. Araki K, Wang B, Miyashita K, Cui Q, Ohno S, Baba H, et al. Frequent loss of heterozygosity but rare microsatellite instability in oesophageal cancer in Japanese and Chinese patients. Oncology. 2004;67(2):151-8.
61. Hayashi M, Tamura G, Jin Z, Kato I, Sato M, Shibuya Y, et al. Microsatellite instability in esophageal squamous cell carcinoma is not associated with hMLH1 promoter hypermethylation. Pathol Int. 2003;53(5):270-6.
62. Lu N, Hu N, Li WJ, Roth MJ, Wang C, Su H, et al. Microsatellite alterations in esophageal dysplasia and squamous cell carcinoma from laser capture microdissected endoscopic biopsies. Cancer Lett. 2003;189(2):137-45.
63. Mathew R, Arora S, Mathur M, Chattopadhyay TK, Ralhan R. Esophageal squamous cell carcinomas with DNA replication errors (RER+) are associated with p16/pRb loss and wild-type p53. J Cancer Res Clin Oncol. 2001;127(10):603-12.
64. Kagawa Y, Yoshida K, Hirai T, Toge T, Yokozaki H, Yasui W, et al. Microsatellite instability in squamous cell carcinomas and dysplasias of the esophagus. Anticancer Res. 2000;20(1A): 213-7.
65. Nakashima H, Mori M, Mimori K, Inoue H, Shibuta K, Baba K, et al. Microsatellite instability in Japanese esophageal carcinoma. Int J Cancer. 1995;64(4):286-9.
66. Tzao C, Hsu HS, Sun GH, Lai HL, Wang YC, Tung HJ, et al. Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutS homolog 2 in resected esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2005;130(5):1371.
67. Zhang GY, Ma CX, Liu QL, Le XP, Ding Y, Zhang QX. Detection of methylation of hMSH2 gene promoter region of esophageal cancer. Zhonghua Zhong Liu Za Zhi. 2005;27(9): 541-3.
68. Ling ZQ, Li P, Ge MH, Hu FJ, Fang XH, Dong ZM, et al. Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer. Dig Dis Sci. 2011;56(10):2992-3004.
69. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296-307.
70. Hegi ME, Sciuscio D, Murat A, Levivier M, Stupp R. Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res. 2009;15(16):5026-31.
71. Roth MJ, Abnet CC, Hu N, Wang QH, Wei WQ, Green L, et al. p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncol Rep. 2006;15(6):1591-7.
72. Fang MZ, Jin Z, Wang Y, Liao J, Yang GY, Wang LD, et al. Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol. 2005;26(3):615-22.
73. Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D. Inactivation of DNA repair gene O-6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis. 2003;24(6):1039-44.
74. Wang JX, He YL, Zhu ST, Yang S, Zhang ST. Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17(37):4225-30.
75. Meng Y, Wang QG, Wang JX, Zhu ST, Jiao Y, Li P, et al. Epigenetic inactivation of the SFRP1 gene in esophageal squamous cell carcinoma. Dig Dis Sci. 2011;56(11):3195-203.
76. Hussain S, Singh N, Salam I, Bandil K, Yuvaraj M, Akbar Bhat M, et al. Methylation-mediated gene silencing of suppressor of cytokine signaling-1 (SOCS-1) gene in esophageal squamous cell carcinoma patients of Kashmir valley. J Recept Signal Transduct Res. 2011;31(2):147-56.
77. Chang X, Yamashita K, Sidransky D, Kim MS. Promoter methylation of heat shock protein B2 in human esophageal squamous cell carcinoma. Int J Oncol. 2011;38(4):1129-35.
78. Chan SH, Yee Ko JM, Chan KW, Chan YP, Tao Q, Hyytiainen M, et al. The ECM protein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome. Int J Cancer. 2011;129(3):565-73.
79. Sung CO, Han SY, Kim SH. Low expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol. 2011;18(1):273-81.
80. Haruki S, Imoto I, Kozaki K, Matsui T, Kawachi H, Komatsu S, et al. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma. Carcinogenesis. 2010;31(6):1027-36.
81. Guo M, Ren J, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics. 2008;3(6):336-41.
82. Zhao BJ, Tan SN, Cui Y, Sun DG, Ma X. Aberrant promoter methylation of the TPEF gene in esophageal squamous cell carcinoma. Dis Esophagus. 2008;21(7):582-8.
83. Ninomiya I, Kawakami K, Fushida S, Fujimura T, Funaki H, Takamura H, et al. Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep. 2008;20(6):1489-95.
84. Smith E, De Young NJ, Tian ZQ, Caruso M, Ruszkiewicz AR, Liu JF, et al. Methylation of TIMP3 in esophageal squamous cell carcinoma. World J Gastroenterol. 2008;14(2):203-10.
85. Wong VC, Chan PL, Bernabeu C, Law S, Wang LD, Li JL, et al. Identification of an invasion and tumor-suppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int J Cancer. 2008;123(12):2816-23.
86. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, et al. The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer. 2008;123(4):753-9.
87. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res. 2005;65(11):4963-8.
88. Tonomoto Y, Tachibana M, Dhar DK, Onoda T, Hata K, Ohnuma H, et al. Differential expression of RUNX genes in human esophageal squamous cell carcinoma: downregulation of RUNX3 worsens patient prognosis. Oncology. 2007;73(5-6): 346-56.
89. Sugiura H, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Mori Y, et al. Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 2008;19(3):713-9.
90. Long C, Yin B, Lu Q, Zhou X, Hu J, Yang Y, et al. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest. 2007;25(8):685-90.
91. Park HL, Kim MS, Yamashita K, Westra W, Carvalho AL, Lee J, et al. DCC promoter hypermethylation in esophageal squamous cell carcinoma. Int J Cancer. 2008;122(11):2498-502.
92. Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, et al. HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma. Mol Cancer Res. 2008;6(1):31-41.
93. Kim MS, Yamashita K, Chae YK, Tokumaru Y, Chang X, Zahurak M, et al. A promoter methylation pattern in the N-methyl-D-aspartate receptor 2B gene predicts poor prognosis in esophageal squamous cell carcinoma. Clin Cancer Res. 2007;13(22 Pt 1):6658-65.
94. Jin Z, Mori Y, Hamilton JP, Olaru A, Sato F, Yang J, et al. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer. 2008; 112(1):43-9.
95. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, et al. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res. 2007;13(21): 6293-300.
96. Zhang C, Li K, Wei L, Li Z, Yu P, Teng L, et al. p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma. J Clin Pathol. 2007;60(11):1249-53.
97. Guo M, House MG, Suzuki H, Ye Y, Brock MV, Lu F, et al. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer. 2007;121(6):1219-26.
98. Liu T, Zhang X, So CK, Wang S, Wang P, Yan L, et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis. 2007;28(2): 488-96.
99. Tanaka K, Imoto I, Inoue J, Kozaki K, Tsuda H, Shimada Y, et al. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma. Oncogene. 2007;26(44):6456-68.
100. Smith E, Drew PA, Tian ZQ, De Young NJ, Liu JF, Mayne GC, et al. Metallothionein 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer. 2005;4:42.
101. Mizuiri H, Yoshida K, Toge T, Oue N, Aung PP, Noguchi T, et al. DNA methylation of genes linked to retinoid signaling in squamous cell carcinoma of the esophagus: DNA methylation of CRBP1 and TIG1 is associated with tumor stage. Cancer Sci. 2005;96(9):571-7.
102. Sonoda I, Imoto I, Inoue J, Shibata T, Shimada Y, Chin K, et al. Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res. 2004;64(11):3741-7.
103. Ito T, Shimada Y, Hashimoto Y, Kaganoi J, Kan T, Watanabe G, et al. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res. 2003;63(19):6320-6.
104. Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 2002; 23(10):1695-9.
105. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11(12): 849-64.
106. Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, et al. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res. 2009;15(6):1915-22.
107. Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, et al. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer. 2012;106(1):182-8.
108. Han L, Witmer PD, Casey E, Valle D, Sukumar S. DNA methylation regulates microRNA expression. Cancer Biol Ther. 2007;6(8):1284-8.
109. Chen X, Hu H, Guan X, Xiong G, Wang Y, Wang K, et al. CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer. 2012;130(7):1607-13.
110. Li X, Lin R, Li J. Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer. Dig Dis Sci. 2011;56(10):2849-56.
111. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61(1):33-42.
112. Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discov. 2005;4(4):275-6.
113. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 2006;12(19):5777-85.
114. Sakakura C, Miyagawa K, Fukuda KI, Nakashima S, Yoshikawa T, Kin S, et al. Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene. 2007;26(40):5927-38.
115. Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem. 2010;17(20):2141-51.
116. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63(22):7563-70.
117. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res. 2005;11(19 Pt 1):7033-41.